• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.肯尼亚开始使用拉米夫定、司他夫定和奈韦拉平治疗乙型肝炎和 HIV 合并感染患者的 HBV 拉米夫定耐药情况。
J Viral Hepat. 2011 Oct;18(10):e447-52. doi: 10.1111/j.1365-2893.2011.01466.x. Epub 2011 May 13.
2
Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.在马拉维，接受抗逆转录病毒预防母婴传播的抗逆转录病毒药物预防的 HBV 和 HIV 感染孕妇中出现拉米夫定耐药乙型肝炎病毒突变。
J Med Virol. 2012 Oct;84(10):1553-7. doi: 10.1002/jmv.23365.
3
Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.拉米夫定耐药相关的 HIV-1 感染者接受含拉米夫定的抗病毒治疗后乙型肝炎病毒耐药。
AIDS Patient Care STDS. 2010 Apr;24(4):205-9. doi: 10.1089/apc.2009.0322.
4
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.在马拉维接受一线抗逆转录病毒治疗的艾滋病毒阳性成年人中，乙型肝炎病毒A1亚基因型感染的特点是复制水平高且耐药性迅速出现。
Clin Infect Dis. 2014 Dec 1;59(11):1618-26. doi: 10.1093/cid/ciu630. Epub 2014 Aug 6.
5
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.南部非洲的 HIV-HBV 合并感染以及拉米夫定与替诺福韦为基础的 cART 对 HBV 结局的影响。
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82. doi: 10.1097/QAI.0b013e3182a60f7d.
6
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.HIV-乙型肝炎病毒合并感染患者长期乙型肝炎病毒应答的新见解：乙型肝炎病毒流行地区抗逆转录病毒管理的启示。
J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):98-103. doi: 10.1097/QAI.0000000000002517.
7
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.人类免疫缺陷病毒1型与乙型肝炎病毒合并感染个体中乙型肝炎病毒DNA的病毒动力学：拉米夫定、替诺福韦或联合治疗的相似疗效
Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.
8
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.在HIV/HBV合并感染患者中使用拉米夫定和替诺福韦治疗乙型肝炎：与治疗反应相关的因素
J Viral Hepat. 2007 Mar;14(3):176-82. doi: 10.1111/j.1365-2893.2006.00797.x.
9
Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.喀麦隆一家公共常规诊所中接受抗逆转录病毒治疗的HIV阳性患者的拉米夫定耐药性HBV感染情况。
Antivir Ther. 2012;17(2):321-6. doi: 10.3851/IMP1911. Epub 2011 Sep 23.
10
Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.加纳乙型肝炎病毒/艾滋病毒合并感染患者一线抗逆转录病毒治疗的结局。
J Antimicrob Chemother. 2012 Dec;67(12):2939-42. doi: 10.1093/jac/dks333. Epub 2012 Aug 21.

引用本文的文献

1
A systematic review of Hepatitis B virus (HBV) prevalence and genotypes in Kenya: Data to inform clinical care and health policy.肯尼亚乙型肝炎病毒（HBV）流行率和基因型的系统评价：为临床护理和卫生政策提供信息的数据。
PLOS Glob Public Health. 2023 Jan 31;3(1):e0001165. doi: 10.1371/journal.pgph.0001165. eCollection 2023.
2
The burden of Hepatitis B virus infection in Kenya: A systematic review and meta-analysis.肯尼亚乙型肝炎病毒感染负担：系统评价和荟萃分析。
Front Public Health. 2023 Jan 26;11:986020. doi: 10.3389/fpubh.2023.986020. eCollection 2023.
3
Hepatitis B virus genetic heterogeneity and drug resistance among jaundiced patients at Coast General Teaching and Referral Hospital, Mombasa County, Kenya.肯尼亚蒙巴萨县海岸综合教学与转诊医院黄疸患者中的乙型肝炎病毒基因异质性与耐药性
Int J Health Sci (Qassim). 2021 May-Jun;15(3):20-25.
4
Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.HBV 合并感染在 HIV 感染者中的流行率和负担：一项全球系统评价和荟萃分析。
J Viral Hepat. 2020 Mar;27(3):294-315. doi: 10.1111/jvh.13217. Epub 2019 Dec 22.
5
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action.非洲乙型肝炎病毒（HBV）药物和疫苗逃逸突变的系统评价：紧急行动的呼吁。
PLoS Negl Trop Dis. 2018 Aug 6;12(8):e0006629. doi: 10.1371/journal.pntd.0006629. eCollection 2018 Aug.
6
HBV infection in untreated HIV-infected adults in Maputo, Mozambique.莫桑比克马普托未接受治疗的艾滋病毒感染成人中的乙肝病毒感染情况。
PLoS One. 2017 Jul 31;12(7):e0181836. doi: 10.1371/journal.pone.0181836. eCollection 2017.
7
Slow CD4 T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana.在博茨瓦纳开始基于特鲁瓦达的联合抗逆转录病毒疗法的人类免疫缺陷病毒/乙型肝炎病毒合并感染患者中，CD4 T细胞恢复缓慢
Open Forum Infect Dis. 2016 Aug 16;3(3):ofw140. doi: 10.1093/ofid/ofw140. eCollection 2016 Sep.
8
Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and Non-injection drug users from coastal Kenya.肯尼亚沿海地区感染和未感染HIV-1的注射吸毒者及非注射吸毒者的乙肝病毒血清学特征和基因型
BMC Infect Dis. 2015 Jul 30;15:299. doi: 10.1186/s12879-015-1060-3.
9
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.在马拉维接受一线抗逆转录病毒治疗的艾滋病毒阳性成年人中，乙型肝炎病毒A1亚基因型感染的特点是复制水平高且耐药性迅速出现。
Clin Infect Dis. 2014 Dec 1;59(11):1618-26. doi: 10.1093/cid/ciu630. Epub 2014 Aug 6.
10
Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.资源有限国家的病毒性肝炎与抗病毒治疗的可及性：当前及未来挑战
Future Virol. 2013 Apr;8(4):371-380. doi: 10.2217/fvl.13.11.

本文引用的文献

1
A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.一项比较咨询和报警装置对 HAART 依从性和病毒学结果影响的随机对照试验。
PLoS Med. 2011 Mar;8(3):e1000422. doi: 10.1371/journal.pmed.1000422. Epub 2011 Mar 1.
2
Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.拉米夫定耐药相关的 HIV-1 感染者接受含拉米夫定的抗病毒治疗后乙型肝炎病毒耐药。
AIDS Patient Care STDS. 2010 Apr;24(4):205-9. doi: 10.1089/apc.2009.0322.
3
Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.尼日利亚乙型肝炎病毒感染对人类免疫缺陷病毒抗逆转录病毒治疗反应的影响。
Clin Infect Dis. 2009 Oct 15;49(8):1268-73. doi: 10.1086/605675.
4
Chronic hepatitis B: update 2009.慢性乙型肝炎：2009年更新
Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190.
5
Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis.乙型肝炎病毒感染对艾滋病毒感染者艾滋病进展和死亡率的影响：一项队列研究和荟萃分析
Clin Infect Dis. 2009 Jun 15;48(12):1763-71. doi: 10.1086/599110.
6
Chronic viral hepatitis as a public health issue in the world.慢性病毒性肝炎作为一个全球性的公共卫生问题。
Best Pract Res Clin Gastroenterol. 2008;22(6):991-1008. doi: 10.1016/j.bpg.2008.11.002.
7
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.南非抗逆转录病毒治疗（ART）项目中的乙型肝炎病毒感染与对抗逆转录病毒治疗的反应
Clin Infect Dis. 2008 Dec 1;47(11):1479-85. doi: 10.1086/593104.
8
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.泰国未接受过抗逆转录病毒治疗的HIV/HBV合并感染个体中乙型肝炎联合治疗的随机试验。
Hepatology. 2008 Oct;48(4):1062-9. doi: 10.1002/hep.22462.
9
HIV, hepatitis B and hepatitis C coinfection in Kenya.肯尼亚的艾滋病毒、乙型肝炎和丙型肝炎合并感染情况。
AIDS. 2008 Jun 19;22(10):1221-2. doi: 10.1097/QAD.0b013e32830162a8.
10
Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.乙肝病毒合并感染对HIV感染者高效抗逆转录病毒治疗反应及预后的影响：一项全国性队列研究
HIV Med. 2008 May;9(5):300-6. doi: 10.1111/j.1468-1293.2008.00564.x.

肯尼亚开始使用拉米夫定、司他夫定和奈韦拉平治疗乙型肝炎和 HIV 合并感染患者的 HBV 拉米夫定耐药情况。

HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.

机构信息

Department of Medicine, University of Washington, Seattle, WA 98104, USA.

出版信息

J Viral Hepat. 2011 Oct;18(10):e447-52. doi: 10.1111/j.1365-2893.2011.01466.x. Epub 2011 May 13.

DOI:10.1111/j.1365-2893.2011.01466.x
PMID:21914062
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3177102/
Abstract

Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV-infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty-seven (6.9%) were HBsAg positive and anti-HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤ 10,000 IU/mL. Sustained HBV suppression to <100 IU/mL occurred in 89% of 19 evaluable patients. Resistance occurred in only two subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV-HBV coinfected patients with low baseline HBV DNA levels.

摘要

广泛使用拉米夫定进行抗逆转录病毒治疗可能导致在没有更昔洛韦的流行地区，艾滋病毒 - 乙肝病毒合并感染患者出现乙肝病毒耐药。我们评估了 389 名肯尼亚艾滋病毒感染成年人在开始使用司他夫定、拉米夫定和奈韦拉平进行高效抗逆转录病毒治疗前和治疗后 18 个月的情况。其中 27 人（6.9%）HBsAg 阳性且抗 -HBs 阴性，24 人 HBeAg 阴性，18 人 HBV DNA 水平≤10,000 IU/mL。在 19 名可评估患者中，有 89%的患者持续 HBV 抑制到<100 IU/mL。只有两名患者出现耐药，且两人均具有较高的基线 HBV DNA 水平。拉米夫定耐药可在 HBV 抑制不完全的情况下出现，但在基线 HBV DNA 水平较低的艾滋病毒 - 乙肝病毒合并感染患者中很少观察到。